MODERATE-TO-SEVERE ATOPIC DERMATITIS
Clinical trials for MODERATE-TO-SEVERE ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE-TO-SEVERE ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called rezpegaldesleukin for adults with moderate-to-severe eczema (atopic dermatitis). About 396 participants will receive either the drug or a placebo for 16 weeks, and those who improve may continue treatment for up to a year. The goal is …
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New shot could tame tough eczema in large trial
Disease control OngoingThis Phase 3 trial tests an experimental injection called SHR-1819 in 652 adults with moderate to severe atopic dermatitis (eczema). Half get the drug, half get a placebo. The main goal is to see if it improves skin rash and itch after 16 weeks. If it works, it may offer a new wa…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 15:54 UTC
-
New shot shows promise for severe eczema sufferers
Symptom relief OngoingThis study tests an experimental drug called SHR-1819 in 201 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it can significantly improve skin symptoms and reduce itching. Participants receive either the drug or a placebo, and researchers track sk…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC